Jaap Verweij
机构: Erasmus University Medical Center and Cancer Drug Development Forum
每年引用次数
引用次数
引用: 121,565
H-指数: 138
I10-指数 : 617
出版物: 1,130
Severe tissue necrosis due to extravasation of mitomycin
Bikkers Th , van Geel An , Verweij J , Stoter G
Nederlands Tijdschrift voor Geneeskunde 131 ( 14) 588
5
1987
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
Steward Wp , Schütte J , Bramwell , Mouridsen H
Seminars in Oncology 19 ( 1) 14 -18
8
1992
Primary tracheo-bronchial melanoma.
Jansveld Ca , Breed Wp , Verweij J
Netherlands Journal of Medicine 25 ( 6) 163 -166
6
1982
Review of phase I clinical studies with topotecan.
Rowinsky Ek , Verweij J
Seminars in Oncology 24 ( 6)
31
1997
High-dose chemotherapy in adult sarcomas: no standard yet.
Seynaeve C , Verweij J
Seminars in Oncology 26 ( 1) 119 -133
22
1999
[Vitamin A derivatives: potential prevention and therapy of solid tumors].
Verweij J , Stoter G
Nederlands Tijdschrift voor Geneeskunde 137 ( 16) 798 -799
1993
The multidisciplinary approach to treatment of soft tissue sarcomas.
van Oosterom At , Verweij J
Journal belge de radiologie 75 ( 4) 258 -264
1992
[Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents].
de Jonge Mj , Eskens Fa , Verweij J
Nederlands Tijdschrift voor Geneeskunde 145 ( 46) 2208
1
2001
[Several patients with a metastasised gastrointestinal stroma-cell tumor for whom the tide turned by the introduction of imatinib].
Gelderblom H , Verweij J
Nederlands Tijdschrift voor Geneeskunde 147 ( 42) 2041 -2043
1
2003
Microangiopathic hemolytic anemia and metastasized carcinoma
Verweij J , Stoter G , Speelberg B
Nederlands Tijdschrift voor Geneeskunde 130 ( 48) 2186
1986
Radioimmunodetection in rhabdo- and leiomyosarcoma with 111In-anti-myosin monoclonal antibody complex.
Peter Cox , André Planting , Gerrit Stoter , Mike Pillay
Cancer Research 50 ( 3)
3
1990
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Alex Sparreboom , Kees Nooter , Peter de Bruijn , Gerrit Stoter
Drug Metabolism and Disposition 27 ( 11) 1300 -1305
34
1999
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
Robbert J. van Alphen , Alex Sparreboom , Kees Nooter , Ron H. J. Mathijssen
Clinical Cancer Research 7 ( 8) 2182 -2194
868
2001
Topotecan lacks third space sequestration.
Alex Sparreboom , Maja J. A. de Jonge , Walter J. Loos , Hans Gelderblom
Clinical Cancer Research 6 ( 4) 1288 -1292
5
2000
Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients
Alex Sparreboom , Jacqueline van de Schraaf , Maja J. A. de Jonge , Peter de Bruijn
Clinical Cancer Research 7 ( 5) 1136 -1141
152
2001
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Maja J. A. de Jonge , Chris Twelves , Rosendo Obach , Ramon Salazar
Clinical Cancer Research 9 ( 11) 4101 -4107
35
2003
Limited sampling model for area under the concentration time curve of total topotecan.
Mark J. Ratain , Jos H. Beijnen , Jaap Verweij , Hironobu Minami
Clinical Cancer Research 2 ( 1) 43 -46
24
1996
Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics
Alex Sparreboom , Ron H. J. Mathijssen , Mats O. Karlsson , Sharyn D. Baker
Clinical Cancer Research 9 ( 9) 3246 -3253
225
2003
Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies
Alex Sparreboom , Wataru Yamamoto , Maja J. A. de Jonge , Peter de Bruijn
Clinical Cancer Research 6 ( 9) 3451 -3458
63
2000
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin
Alex Sparreboom , Maja J. A. de Jonge , Maureen M. de Boer-Dennert , Peter de Bruijn
Clinical Cancer Research 5 ( 8) 2012 -2017
18
1999